Evidence map›Paper›PMID 39550373›Full record

ArticleScientific reports2024

Symptom trajectories over time by cannabis use status among patients undergoing cancer treatment.

Taylor Niznik, Laili K Boozary, Meng Chen, Amy M Cohn, Susanna V Ulahannan, Christina E Henson, Adam C Alexander, Kathleen N Moore, Laura L Holman, Lurdes Queimado and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Taylor NiznikTSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Laili K BoozaryTSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Meng ChenTSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Amy M CohnTSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Susanna V UlahannanDepartment of Internal Medicine, Hematology-Oncology Section, Stephenson Cancer Center, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Christina E HensonDepartment of Radiation Oncology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Adam C AlexanderTSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Kathleen N MooreDepartment of Obstetrics and Gynecology, Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Laura L HolmanDepartment of Obstetrics and Gynecology, Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Lurdes QueimadoTSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Darla E KendzorTSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA. Darla-Kendzor@ouhsc.edu.

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
HealthyCells: A Culturally-Tailored Smoking Cessation Smartphone Intervention for African Americans with Adjunctive Treatment for Sedentary BehaviorK01MD015295 · NIMHD · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ALEXANDER, ADAM C · 2021 to 2025
$670k
National Cancer Institute Cancer Center Support P30CA225520NCI NIH HHS P30 CA225520NIMHD NIH HHS 1K01MD015295-01A1NIMHD NIH HHS K01 MD015295Oklahoma Tobacco Settlement Endowment Trust R22-03
6 · The paper itself

Abstract

Adults with cancer may perceive cannabis as beneficial for managing their cancer-related symptoms, but the evidence supporting its medical use is varied and inconclusive. This study characterized associations of cannabis use with cancer-related symptom trajectories. Participants were adults undergoing cancer treatment at the Stephenson Cancer Center (SCC; n = 218) in Oklahoma; they were 71% female, 10% minoritized race, and 45% had stage III or IV cancer. Participants completed surveys at baseline and 2-, 4-, and 6-months post-baseline. Assessments queried about cannabis use behavior, physical and psychological distress via the Rotterdam Symptoms Checklist (RSCL), respiratory symptoms via the American Thoracic Society Questionnaire (ATSQ), and quality of life indices (physical and social functioning, pain interference, sleep quality, fatigue) via the Patient Reported Outcomes Measurement Information System (PROMIS-29). Cannabis use status was categorized based on self-reported past 30-day cannabis use at each assessment as non-use [no use at any assessment], occasional-use [use at 1-2 assessments], or consistent-use [use at 3-4 assessments]. Longitudinal hierarchical linear modeling evaluated associations of cannabis use status with average symptoms and symptom trajectories across all four assessments. One-third (33%) of participants reported past 30-day cannabis use at ≥ 1 assessment. Participants who reported cannabis use (occasional-use and consistent-use) had more severe symptoms overall across assessments. While most cancer symptom trajectories did not differ by cannabis use status, participants who reported consistent cannabis use uniquely showed worsening physical function over time. Cannabis use was associated with greater cancer-related symptom severity over time.

Indexed as

NeoplasmsQuality of LifeAdultAgedCannabisFemaleHumansMaleMarijuana UseMiddle AgedSurveys and QuestionnairesCancerCannabisPainPhysical functioningSleep disturbance

Identifiers

PMID39550373
PMCPMC11569142

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.